Agios Pharmaceuticals Shares Plunge After Mixed Sickle Cell Trial Results

Shares of Agios Pharmaceuticals, Inc. experienced a dramatic decline on Wednesday, falling by 51% to close at $22.34. This significant drop followed the release of mixed results from a late-stage clinical trial of its sickle cell disease treatment, Mitapivat. The market responded negatively to the company’s announcement, which revealed that while the drug met the primary endpoint for hemoglobin response, it failed to show significant improvements in pain crises and fatigue.

Investors reacted swiftly as analysts adjusted their outlooks on Agios. Bank of America Securities (BofA) lowered its price target from $54 to $32 while maintaining a ‘Buy’ rating. The firm’s analysis stated that the RISE UP study demonstrated a statistically significant improvement in hemoglobin levels but noted only “modest directional benefit” regarding the reduction of pain crises and fatigue. BofA emphasized that these results suggest a more uncertain regulatory path ahead for Agios.

Analysts Downgrade Agios Amid Uncertainty

RBC Capital also revised its stance on Agios, downgrading the stock from ‘Outperform’ to ‘Sector Perform’ and slashing its price target to $28 from $57. The firm highlighted that although Mitapivat shows activity, it did not meet the critical endpoints for patient outcomes, such as crisis reduction and hospitalization rates. RBC’s evaluation reflects a lowered likelihood of success for the sickle cell program, which could impact the drug’s market uptake even if it eventually receives approval.

H.C. Wainwright cut its price target from $56 to $48, yet maintained a ‘Buy’ rating. The firm described the market’s reaction as “overdone,” expressing cautious optimism about the drug’s potential approval, particularly given the precedent set by Oxbryta and the absence of new safety issues, although it acknowledged increased uncertainty surrounding the data.

The mixed results stemmed from the Phase 3 RISE UP study, one of the two pivotal trials Agios plans to complete before 2025. While the primary endpoint for hemoglobin response was achieved with a statistically significant improvement compared to placebo, the study did not indicate a significant reduction in pain crises or improvement in fatigue, both of which are vital quality-of-life metrics for patients.

Competitors and Market Sentiment

As Agios faces challenges, competitors are gaining traction. Leerink highlighted early Phase 1b data for Fulcrum Therapeutics’ pociredir, indicating a potentially favorable efficacy profile compared to Mitapivat. Similarly, Oppenheimer noted that the disappointing results for Agios could alleviate competitive pressure for Fulcrum, particularly as both studies showed marginal improvements in hemoglobin without statistical significance for vaso-occlusive crises.

Retail investor sentiment on platforms like Stocktwits reflected a more bullish outlook, with a surge of 6,400% in message volume discussing Agios. Some investors expressed their intent to buy the dip ahead of the upcoming FDA submission planned for December 6, 2025. One user noted, “I’ll load more tomorrow and Friday. Need to be ready for the FDA approval. Should skyrocket!!!” Others argued that the selloff was excessive, emphasizing that the strong hemoglobin response and clean safety profile still support a viable path to approval.

As the situation develops, Agios Pharmaceuticals will need to navigate these challenges carefully, particularly as it prepares to share its complete clinical program with the FDA in the first quarter of 2026. The mixed trial results have raised significant questions about the future of Mitapivat and its impact on the company’s prospects in the competitive landscape of sickle cell disease treatments.